Myeloma comparative sequencing points to Plexxikon now, personal therapies later
This article was originally published in Scrip
Executive Summary
A multi-patient whole genome analysis study in multiple myeloma recently published in Nature which is "just the beginning" of a deeper understanding of the disease, according to its authors, has already identified an entirely new potential molecular target and given a clear signal that a drug currently showing promise in melanoma might also be effective in a significant minority of multiple myeloma patients. The publication represents the first time that multiple cancer of the same time have been comparable at the whole genome level.